Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Sarepta (SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
August 8, 2019 12:10 PM EDTSarepta's (NASDAQ: SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
Sarepta Therapeutics (SRPT) Tops Q2 EPS by 54c
August 7, 2019 5:38 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.83), $0.54 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $94.7 million versus the consensus estimate of $90.94 million.
As we pass through mid-2019, we are very pleased to announce strong performance and solid execution against our goals. EXONDYS 51®(eteplirsen) continues to perform, with second quarter sales at $94.7 million, 29% growth quarter over same quarter last year. In our RNA franchise, we... More
